Chairman of Precision Biotech (Cell Therapy) Professor Ming-Kung Yeh has won the honor of World’s Top 2% Scientists for three consecutive years.International medical director of Care bridge Institute (Boston, USA) Deputy Chief Executive Officer of the Medical Management Committee of the Ministry of Health and Welfar of Taiwan and Consultant of Taipei Hospital. Executive Secretary of Technical Supervision and and Health Insurance Association of Ministry of Health and Welfare of Taiwan

Director of Food and Drug Administration of Ministry of Health and Welfare of Taiwan Director of Drug Administration of Military Medical Bureau of Ministry of Defense of Taiwan Member of Health Care Committee and Public Issues Committee of Taiwan Consumer Foundation .Co-appointed Professor of Taiwan National Defense Medical Center (T 015541) Doctor of Pharmacy, Nottingham University, UK (1996) Visiting Professor of University of Cincinnati (2002-03), Visiting Professor of Massachusetts General Hospital (2016)

Member of the Research Ethics Committee of Tzu Chi General Hospital in Daelim Province

Associate Researcher, Department of Medical Research, Tzu Chi General Hospital, Daelim DistrictProject researcher at National Cheng Kung University's Prospective Medical Device Technology CenterPostdoctoral researcher at the Institute of Molecular Biology, National Chung Cheng University Postdoctoral researcher at the Institute of Molecular Biology, Academia Sinica Ph.D., Institute of Biotechnology, National Chung Hsing University.

Postdoctoral researcher at the Department of Obstetrics and Gynecology, School of Medicine, National Taiwan University,Postdoctoral researcher in cell and systems medicine, National Institute of Health Ph.D., Institute of Molecular Medicine, National Tsing Hua University.

Clinical Leader MBA in Medicine, Graduated from Renmin University of China, National Licensed Pharmacist, Senior Engineer Research Field: Pharmaceutical Preparations and Clinical Application, Clinical Research of Cell Therapy, Research on Infantile Hemangioma (the first pharmacokinetic study for infants and young children in China) Experience: Director of Suzhou Dongrui Pharmaceutical Preparation Research Office, Dongrui Pharmaceutical (Holdings) Co., Ltd. Contact person of public affairs department of Shanghai Fosun Pharma Group (registration, clinical) Director of Strategic Development Department of Suzhou Erye Pharmaceutical, Shanghai Fosun Pharmaceutical Group Director of Public Affairs Department of Suzhou Erye Pharmaceutical, Shanghai Fosun Pharmaceutical Group (registration, clinical, market access) Executive Director of the 8th Council of Shanghai Jiangsu Biotechnology Association Founder of Suzhou MaiDeTong Pharmaceutical Technology Co., Ltd. Experience: more than 30 years

Doctor of Surgery, Army Medical University

He is engaged in postdoctoral work at West China School of Pharmacy, Sichuan University

He has undertaken a number of major projects of the National Natural Science Foundation of China, 973 projects, major new drug projects, and provincial and municipal science and technology development projects Scientific research Cheng Ling has won the second prize of military scientific and technological progress, and has obtained a number of domestic and foreign invention patents.

Ph.D. in Neuropharmacology, School of Pharmacy, Shenyang Pharmaceutical University

Clinical research fields such as psychoneurological, respiratory, circulatory, endocrinology, hematology, oncology, anti-infection, and topical preparations.

He has successively served as a pharmacology researcher, pharmacy supervisor, registration manager, clinical senior manager, clinical deputy director, clinical director and other positions of pharmaceutical enterprises, leading clinical operations and taking care of clinical medical work; Participation includes product research and evaluation, patent analysis, pharmaceutical guidance, etc. Independently develop in vitro and in vitro correlation risk prediction software tools, and is good at predicting drug behavior and clinical risks in vivo from pharmaceutical and pharmacokinetic data. The industry has more than 15 years of experience

Institute of Biomedical Research, Chang Gung University

Cell biology, molecular biology, tumor biology, cell therapy and clinical trial development

Researcher at Ivy Life Sciences Co., Ltd

Postdoctoral researcher at Chang Gung University

Full-time research assistant at Chang Gung University

Ph.D. in Molecular Medicine, National Yangming University

Ph.D. dissertation and postdoctoral research topic: The physiological and pathological role of type 2 innate lymphocytes (ILC2) in the lungs, heart and kidneys.

Postdoctoral research at the Institute of Biomedical Translation, Kaohsiung Chang Gung Hospital

Researcher at Kaohsiung Laboratory, Ivy Life Science Co., Ltd. (one-year RAISE program).